CAR-NK cell therapy for relapsed or resistant B-cell acute lymphoblastic leukemia
Treatments studied
Part of Blood & lymphatic, Cancer clinical trials.
This trial tests a new treatment using specially engineered immune cells (CAR-NK cells) that are designed to find and destroy leukemia cells. It may be an option for patients whose leukemia has come back or hasn't responded to other treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have B-cell acute lymphoblastic leukemia (B-ALL) that is CD19-positive, meaning the leukemia cells have a specific marker called CD19.
- You are 3 years old or older.
- Doctors expect you to live at least 12 more weeks.
- You are generally able to perform daily activities (ECOG score 0-2 or Karnofsky score greater than 60).
- If you are a woman who can have children, you must have a negative pregnancy test and agree to use effective birth control for up to two weeks after the last infusion.
- Your blood counts, liver, and kidney function must be within certain ranges.
- You do not have active infections like HIV, hepatitis B, or hepatitis C.
- You do not have serious medical conditions (like uncontrolled infection, heart problems, bleeding issues, or severe psychiatric conditions) that would make this treatment unsafe.
- You are not currently taking systemic steroids (inhaled steroids are okay).
- You have not had fludarabine or cladribine chemotherapy within 3 months before the procedure.
- You must be able to give informed consent (or have a parent/guardian do so).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new type of immune cell therapy called CAR-T cells that are designed to find and destroy cancer cells with the CD19 or CD22 markers. The goal is to see if this experimental treatment can help people with B-cell acute lymphoblastic leukemia or non-Hodgkin's lymphoma when other treatments haven't worked.
This trial tests a new type of immunotherapy called CAR-T cells, which are made from your own blood cells and trained to find and destroy leukemia cells. It is for adults with B-cell acute lymphoblastic leukemia (B-ALL) that has come back or not responded to standard treatments.
This Phase 1 study tests a new immune-cell treatment made from donated cord blood. It aims to treat people whose B-cell lymphoma has come back or did not respond, specifically when the tumor has CD19 on it.
This trial tests a new type of immune cell therapy (CAR-T) that targets two proteins on cancer cells—CD19 and CD22—to treat lymphoma or leukemia that has come back or not responded to standard treatment. It aims to see if this two-target approach works better.
This trial tests whether CAR-T cells made from a healthy donor can help treat B-cell acute lymphoblastic leukemia that has come back or not responded to treatment. It's for adults who cannot use their own cells for CAR-T therapy.
This trial tests a new way to treat B-cell acute lymphoblastic leukemia (B-ALL). The treatment takes your own immune cells, changes them to fight cancer, and then gives them back to you. The goal is to kill leukemia cells and help you go into remission.
Hear when a new Acute Lymphocytic Leukemia in Relapse trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.